Takeda Partners with BridGene Biosciences to Identify Novel Small Molecules in Immunology and Neurology

Shots:

• Takeda has entered into strategic collaboration & licensing agreement with BridGene bioscience to identify novel small molecules in immunology & neurology
• As per the terms, Takeda will gain exclusive rights to develop & commercialize products arising from the deal in exchange for $46M including upfront & preclinical milestone, plus additional ~$770M in clinical & commercial milestones if all milestones are met, as well as net sales-based tiered royalties
• Collaboration will leverage BridGene’s Imtac platform & its chemoproteomics-based approach to screen small molecules across all proteins in live cells to tackle traditionally undruggable or ‘hard-to-drug’ targets

Ref: Prnewswire | Image: BridGene & Takeda

Related News:- Neurocrine Biosciences and Takeda Amend Partnership to Develop and Commercialize Osavampator in Japan

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com